Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration Regimen

Ram, C. Venkata S.; Sachson, Richard; Littlejohn, Thomas; Qian, Chunlin; Shojaee, Ali; Stoakes, Kathy A.; Neutel, Joel M.

doi:10.1016/j.amjcard.2010.12.045

Cited by 28 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At baseline, the mean 24-hour ABP was 144.4/81.6 mm Hg. After 12 weeks of active treatment, the mean ABP was significantly reduced by –19.9/–11.2 mm Hg (p < 0.0001 vs. baseline), with 72% of patients titrated to triple therapy (AML/OM + HCTZ) [53]. Approximately 70% of the patients achieved a 24-hour ABP target of <130/80 mm Hg.…”

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

“…An ambulatory BP (ABP) monitoring study assessed the efficacy of an AML/OM ± HCTZ combination therapy in patients with hypertension and T2DM [53]. At baseline, the mean 24-hour ABP was 144.4/81.6 mm Hg.…”

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

“…Approximately 70% of the patients achieved a 24-hour ABP target of <130/80 mm Hg. The seated cuff (Se) BP goal of <130/80 mm Hg for patients with T2DM was achieved by 62% of the patients after 18 weeks of treatment [53]. Blacks and Hispanics comprised 17 and 26% of the study population, respectively [53], and 81% of the patients had MetS [54].…”

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

See 2 more Smart Citations

Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy

Ferdinand

2012

Cardiorenal Med

View full text Add to dashboard Cite

Cardiorenal metabolic syndrome (CRS) is a global health care concern in view of aging in certain populations, increased obesity, changing lifestyles, and its close association with type 2 diabetes mellitus and cardiovascular morbidity and mortality. Determining the appropriate criteria for CRS has been somewhat controversial, and efforts to fully describe and define the syndrome are still ongoing. Nonetheless, improving knowledge of the syndrome among health care professionals will help to identify patients who may require pharmacological and therapeutic lifestyle intervention, particularly with regards to addressing high-normal blood pressure and hypertension. This article reviews current clinical guidelines with a focus on the identification, especially in racial/ethnic minorities, treatment, and associated cardiovascular morbidity and mortality of high blood pressure and hypertension in patients with CRS. Efficacy and outcomes studies that provide insight into the selection of an initial antihypertensive regimen in this population will be discussed. Finally, a brief review of the benefits of olmesartan medoxomil and combination therapy and patient factors in the management of hypertension with CRS will be addressed.

show abstract

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

Section: Recent Olmesartan Medoxomil Efficacy Studies Supporting a Ramentioning

confidence: 99%

See 1 more Smart Citation

Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy

Ferdinand

2012

Cardiorenal Med

View full text Add to dashboard Cite

show abstract

“…23 Recently, evidence from the literature has suggested that the triple combination of OM, AML and HCTZ is an effective and safe treatment option, because it involves drugs whose mechanisms of action are complementary and synergic. [24][25][26][27][28][29][30][31][32][33][34] …”

Section: Clinical Studiesmentioning

confidence: 99%

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Gomes¹,

Paiva²,

Campana³

et al. 2012

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

Abstract:The guidelines and consensus documents on hypertension management have emphasized the need for a better arterial hypertension (AH) control, and, thus, have recommended an optimized treatment, which usually requires the combined use of drugs that block different mechanisms responsible for blood pressure (BP) increase. For stage 2 and 3 hypertensives, the association of two drugs is mandatory, and if the BP goal is not attained, the association of a third drug is the preferential option. For high CV risk patients, the current tendency is to block the renin-angiotensin-aldosterone system (RAAS) with an angiotensin-converting-enzyme inhibitor (ACEI) or with an angiotensin II type 1 receptor blocker (ARB) or even with a direct renin inhibitor (DRI), associated with a calcium channel blocker (CCB). When the BP goal is not reached with this type of association, a diuretic compound is the drug to be added. The triple combination of Olmesartan (OM), amlodipine (AM)L, and hydrochlorothiazide (HCTZ) seems to be one of the most adequate choice, due to the complementary mechanisms of action of their agents. This study aimed at reviewing both the rationale for the combined use of drugs for controlling AH and the results of the clinical trials on the triple association of OM, AML, and HCTZ.

show abstract

“…It is given in oral doses of 10mg to 20mg once daily for the management of hypertension 2 . Clinical trials on hypertensive patients revealed that OLM has a good tolerance without any serious side effects 3 .…”

Section: Introductionmentioning

confidence: 99%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

ABSTRACT:Olmesartan medoxomil (OLM) is a lipophilic (log P = 4.31) antihypertensive drug suffering from limited oral bioavailability in humans (26%) due to its low aqueous solubility, uncontrolled enzymatic conversion to the active metabolite (Olmesartan; OL) and efflux by drug resistance pumps. Surmounting such limitations via incorporation of OLM into selfnanoemulsifying drug delivery systems (SNEDDS). Based on OLM-equilibrium solubility studies in various oils, surfactants and co-surfactants, Capmul ® MCM, Tween ® 20, Cremophor ® EL and polyethylene glycol -400 (PEG) were combined in different ratios to plot ternary phase diagrams. OLM-loaded SENDDS were developed and evaluated forparticle size, polydispersity index (PDI), zeta potential, self-emulsification time, morphology, drug released percentages after 5-min (Q 5min %), 1 hour (Q 1h %) and dissolution efficiency percentages (DE 1h %). The OL pharmacokinetics from SNEDDS (F6) and Benicar ® tablets were evaluated (LC-MS/MS) in rabbits. Spherical OLM-loaded SNEDDS were developed. The best-achieved SNEDDS (F6) showed short emulsification time (13 s), fine droplet size (60.00nm), low PDI (0.25), negative zeta potential (-14.4mV), promising dissolution parameters; Q 5min % (29.78%), Q 1h % (66.69%) and DE 1h % (47.96%) and enhanced in vivo absorption characteristics; shorter T max , higher C max and larger AUC (0−48h ; suggesting its potential for the enhancement of the oral absorption of practically insoluble drugs; like OLM.

show abstract

Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration Regimen

Cited by 28 publications

References 14 publications

Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy

Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Untitled

Contact Info

Product

Resources

About